FDA: J&J’s Ditropan Labeling Should Be Strengthened To Advise Of Hallucinations
This article was originally published in The Pink Sheet Daily
Executive Summary
Documents issued ahead of a Pediatric Advisory Committee meeting April 11 urge stronger caution due to CNS effects of oxybutynin.
You may also be interested in...
J&J Ditropan XL Goes Generic
Impax/Teva launching 15 mg strength, and Mylan joins with "authorized" generic as well as its own version of the 5 mg and 10 mg strengths.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.